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Abstract
Background: Theme-driven cancer survival studies address whether the expression signature of genes related to a
biological process can predict patient survival time. Although this should ideally be achieved by testing two
separate null hypotheses, current methods treat both hypotheses as one. The first test should assess whether a
geneset, independent of its composition, is associated with prognosis (frequently done with a survival test). The
second test then verifies whether the theme of the geneset is relevant (usually done with an empirical test that
compares the geneset of interest with random genesets). Current methods do not test this second null hypothesis
because it has been assumed that the distribution of p-values for random genesets (when tested against the first
null hypothesis) is uniform. Here we demonstrate that such an assumption is generally incorrect and consequently,
such methods may erroneously associate the biology of a particular geneset with cancer prognosis.
Results: To assess the impact of non-uniform distributions for random genesets in such studies, an automated theme-
driven method was developed. This method empirically approximates the p-value distribution of sets of unrelated genes
based on a permutation approach, and tests whether predefined sets of biologically-related genes are associated with
survival. The results from a comparison with a published theme-driven approach revealed non-uniform distributions,
suggesting a significant problem exists with false positive rates in the original study. When applied to two public cancer
datasets our technique revealed novel ontological categories with prognostic power, including significant correlations
between “fatty acid metabolism” with overall survival in breast cancer, as well as “receptor mediated endocytosis”, “brain
development”, “apical plasma membrane” and “MAPK signaling pathway” with overall survival in lung cancer.
Conclusions: Current methods of theme-driven survival studies assume uniformity of p-values for random
genesets, which can lead to false conclusions. Our approach provides a method to correct for this pitfall, and
provides a novel route to identifying higher-level biological themes and pathways with prognostic power in clinical
microarray datasets.
Background
In clinical oncology, the discovery of knowledge from
gene expression microarray e x p e r i m e n t si so f t e nb a s e d
on what has been described a “top-down” or hypothesis-
free approach, where a prognostic model is derived
from global tumour gene expression data in a way that
does not require a priori knowledge of biological func-
tion [1]. A subsequent goal is to extract one or more
higher-level biological “themes” from this primary
model. In practice the task of inferring themes regarding
biological function from a prognostic geneset, which
may consist of a relatively small number of genes repre-
senting very distinct biological processes, has proved to
be a major analytical bottleneck.
A contrasting approach is a “bottom-up” or hypoth-
esis-driven method where sets of biologically-related
genes (e.g. all transcripts coding for proteins of a parti-
cular signalling pathway) are defined first, and then
these sets of genes are analysed to determine if any set
acts as a prognostic indicator. Since the biological func-
tions of the genesets are already known, sets with prog-
nostic power can then play a more informative role in
clinical decision-making [1]. We will refer to this * Correspondence: kiplingd@cardiff.ac.uk
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gical function of a geneset becomes a theme, so as to
distinguish it from other geneset-based methods in
which genes do not share common functionality.
Although useful in principle, a theme-driven approach
in clinical oncology has not been widely used until
recently, mainly due to the difficulty of defining sets of
genes of common cellular function. However, the emer-
gence of function-oriented classifications of genes, such
as those developed by the Biocarta [2], Gene Ontology
(GO) [3], Gene Map Annotator and Pathway Profiler
(GenMAPP) [4], and Kyoto Encyclopedia of Genes and
Genomes (KEGG) [5] consortia, in addition to those
commercially available (e.g. Ingenuity [6], GeneGO [7]),
has facilitated the comprehensive analysis of collections
of biologically-related genes.
Common methods of theme-driven cancer survival
analysis can involve clustering to segregate cancer sam-
ples into two groups according to the gene expression
levels of the geneset of interest, and a subsequent survival
test to determine whether a difference in prognosis exists
between both groups [8,9]. It is important to clarify what
it is being tested in such studies. This type of experi-
ments has two inherent null hypotheses. Goeman and
Bühlmann [10] have discussedt h e s et w ov e r yd i f f e r e n t
hypotheses, which result from analysing genesets in
terms of subject-sampling and gene-sampling models.
Although discussed in a different context, the implica-
tions are relevant to any geneset analysis of gene expres-
sion microarray data. According to the authors, in a
subject-sampling model the subjects (i.e. tissue samples
or patients) are treated as the sampling units, and it is
natural to formulate a self-contained null hypothesis. In
the authors’ example, this null hypothesis states that a
geneset is not differentially expressed. A significant p-
value against this self-contained null hypothesis would
mean that the same association found for the subjects
analysed would also be found for a new set of subjects
with high certainty. Yet, this p-value does not make any
statement about how the geneset relates to others. On
the other hand, in a gene-sampling model the genes
become the sampling units, and it is straightforward to
formulate a competitive null hypothesis. This hypothesis
states that a particular geneset is differentially expressed
as often as other genesets. In this case, a significant p-
value would mean that the geneset would still be differ-
entially expressed for the same subjects when new sets of
genes are included on a new microarray. However, this
p-value does not imply that the same association would
be found for a new set of subjects. Throughout this
paper, the expressions p-value1 and p-value2 will refer to
p-values obtained from the first (self-contained) and the
second (competitive) hypothesis tests, respectively. The
expression p-value will be used in general terms.
In theme-driven survival studies, the two null hypoth-
eses (with an exception mentioned below) must be
tested. The first null hypothesis, which is self-contained
and based on subject-sampling, claims that a particular
geneset, independent of its composition (i.e. made up of
either biologically-related or random genes), has no pre-
dictive power of survival time. A survival test, such as a
log-rank test, is the usual choice for testing this hypoth-
esis. A significant p-value1 for a geneset would give one
confidence that the association between the geneset and
survival would also be found for new patients, but it does
not demonstrate that the theme of the geneset is actually
r e l e v a n t .T h i si sa d d r e s s e dw i t hac o m p e t i t i v en u l l
hypothesis based on gene-sampling. This second null
hypothesis states that a set of biologically-related genes
is, at most, as correlated with survival as are random sets
of unrelated genes. This hypothesis can be tested by an
empirical test that compares the correlation to survival of
a given geneset with that of random sets of unrelated
genes. A significant p-value2 against this hypothesis
would mean that the theme of the geneset is associated
with survival time, but only for the patients analysed in
the dataset. Therefore, both null hypotheses must be
rejected in order to claim predictive power of a theme.
If the distribution of p-values1 for random sets of unre-
lated genes is uniform, which in turn implies that most
sets of unrelated genes are non-informative with respect
to survival, testing for the second null hypothesis
becomes redundant. To illustrate this point with an
example, assume that a biologically-related geneset g has
prognostic power as assessed by rejecting the first null
hypothesis at a p-value1 p = 0.004 below a significance
threshold a. If this geneset is systematically compared to
n = 1000 non-informative (random) genesets (i.e. testing
the second null hypothesis), it will outperform them
approximately (1 - p)×n = 996 times (assuming a uni-
form distribution of p-values1 for non-informative gene-
sets). It is expected that 4 random genesets will be at
least as significant as geneset g, which means that the
empirical p-value2 for g will also be equal to 4/1000, that
is, 0.004 (see Methods). Since p-value1 and p-value2 are
equal, it would be enough to only test the first null
hypothesis. However, it has been reported that the distri-
bution of p-values is often not uniform in gene expres-
sion experiments [11], which questions the adequacy of
current theme-driven survival methods that assume uni-
formity. In our study, we are therefore interested in the
distribution of p-values1 for random sets of unrelated
g e n e s ,s i n c eb yi n c o r r e c t l ya s s u m i n gau n i f o r md i s t r i b u -
tion of these p-values1, a researcher may falsely conclude
that the theme of a geneset has prognostic power.
One situation that may lead to false positive conclu-
sions in theme-driven survival analysis is when there are
widespread changes in gene expression that lead to the
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tive manner. Take as an extreme example a dataset con-
sisting of two tumour types: benign early lesions and
aggressive metastatic disease. Assume that the degree of
transcriptome changes is so great that the data for any
randomly selected group of genes clusters in such a way
as to separate the patients into benign and aggressive
categories. In such a scenario any biologically-based
geneset (say all the genes within a particular GO cate-
gory) might likewise cause an informative clustering of
the data, and thus have prognostic power. The erro-
neous conclusion would be that this particular GO gen-
eset has prognostic power greater than a random
geneset, that is, the biological process (i.e. the theme of
this geneset) is associated with prognosis. Formally
speaking, the error has been caused by assumptions
regarding the distribution of the p-values1 for random
sets of unrelated genes.
Although this hypothetical experiment is somewhat
extreme, it illustrates the caution that must be taken
when interpreting the p-values from simple applications
of theme-driven survival techniques. The key to a more
rigorous approach is to model the distribution of p-
values1 for random genesets, so as to then also provide
accurate empirical p-values2 for the biologically-related
genesets. Although some hypothesis-free studies [12,13]
and some geneset-based experiments focusing on differ-
ential expression patterns [14] have implicitly dealt with
the possible non-uniform distribution of p-values1 for
random genesets, theme-driven cancer survival studies
have not, to date, acknowledged this problem.
Therefore, in this study we set out to investigate the
distribution of p-values1 for random sets of unrelated
genes and its effects on theme-driven cancer survival
methods. Using two publicly available datasets we
demonstrate that such distribution is indeed non-uni-
form. We then describe a method that empirically
approximates this distribution using a permutation
approach based on 100,000 random sets of unrelated
genes. Finally, we apply this methodology to these two
datasets and compare our results with those of a pre-
vious theme-driven study [8]. This study has reported a
significant association of a gene expression signature of
fibroblasts in response to serum (core serum response,
CSR, signature as called by the authors) with patient
survival for many cancer datasets, including the breast
and lung cancer sets used in our study. Our data ques-
tion the validity of some of those associations, since the
method employed in such study assumes that p-values1
for random genesets are uniformly distributed. However,
our data reveal that such assumption is frequently incor-
rect, which may result in erroneous conclusions, and we
provide an empirical methodology to address this
problem.
Results
Each original geneset was tested against the first and the
second null hypotheses. For each geneset, cancer
patients from a breast cancer gene expression study and
a lung cancer study were split in two clusters based on
the expression values of the genes in the geneset, and a
p-value p1 was calculated by comparing survival times
for patients in each cluster with a log-rank test (first
hypothesis test). By taking 100,000 randomly permuted
sets of unrelated genes with the same geneset size distri-
bution as Biocarta, GO, KEGG, and CSR genesets, we
calculated empirical distributions of p-values1 for ran-
dom genesets. Since an association is present between
geneset size and significance (Figure 1, Additional Files
1, 2), the sizes of the randomly generated genesets were
Figure 1 Association between geneset size and significance for breast cancer OS. For each type of geneset (i.e. Biocarta, GO, and KEGG), sets
of random genes of sizes 20, 75, 150, 300, and 500 (the latter omitted for Biocarta because the pool of genes was too small) consisting of 10,000
genesets for each size were generated. For each geneset, hierarchical clustering was performed to segregate samples into two groups, a subsequent
log-rank test was performed to assess a difference in prognosis between both groups, and the p-value1 was recorded. The negative base 10 logarithms
of the p-values1 are plotted against geneset size. Biocarta-like genesets appear to be more significant around length = 150 (A); GO-like genesets do not
show a clear correlation of significance to geneset size (B); KEGG-like genesets seem to be more significant as size becomes smaller (C).
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include the same proportion of geneset sizes in each
empirical distribution. For each original geneset, p1 was
compared with the random p-values1 of the appropriate
distribution and an empirical p-value p2 was calculated
(second hypothesis test). A false discovery rate (FDR)
method was implemented to control for multiple testing
for each hypothesis test, namely FDR1 and FDR2 for the
first and second hypothesis tests, respectively.
Non-uniform distributions for random genesets
As shown in Figure 2, the four empirical distributions of
random genesets (i.e. Biocarta-like, GO-like, KEGG-like,
and CSR-like) for both breast and lung overall survival
(OS), as well as for breast relapse-free survival (RFS,
Additional File 3), deviate considerably from the
expected uniform distribution. Figure 2A and Figure 2B
show the density distributions of p-values1 for breast OS
and lung OS, respectively (Additional File 1A shows the
density distributions for breast RFS). Additional File 4
shows the same density distributions for breast OS and
lung OS but on negative logarithmic scale. It can be
appreciated that the peaks of most distributions occur
around 2, which represents a p-value1 of 0.01 (a com-
monly used significance threshold). A uniform distribu-
tion would mean that p-values1 should be seen at the
same frequency across the entire range 0 < p < 1, hence a
Figure 2 Empirical p-value1distributions of random genesets for breast cancer OS and lung cancer OS. Relative frequency density
distributions are shown for breast cancer OS (A) and for lung OS (B). For each survival estimate (i.e. breast cancer OS, and lung cancer OS), the
relative frequency density estimate with a bandwidth equal to 0.01 is plotted for each empirical distribution (i.e. Biocarta-like, GO-like, KEGG-like,
and CSR-like). A uniformly distributed empirical distribution would result in p-values1 at the same frequency across the entire range 0 < p < 1
(dashed line in (A) and (B)). Ordered plots of empirical p-value1 distributions versus the uniform distribution are shown for breast cancer OS (C)
and for lung cancer OS (D). The permuted p-values used to model each distribution (i.e. Biocarta-like, GO-like, KEGG-like, and CSR-like) are plotted
against random p-values1 from a uniform distribution. An x = y line would be expected if the empirical distributions were uniformly distributed.
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expected. That this is not seen suggests that p-values1 for
random genesets are not uniformly distributed in these
two examples. Instead, there is an excess number of ran-
dom genesets scored as apparently significant (for exam-
ple, with p < 0.01). In addition Figure 2C and Figure 2D
also show the non-uniformity of p-values1 for random
genesets for breast OS and lung OS, respectively (Addi-
tional File 3B shows these results for breast RFS). In
these plots an x = y line would be expected if the empiri-
cal distributions were uniformly distributed, which is
clearly not seen.
First hypothesis and second hypothesis tests
Table 1 shows a summary of results for the original gen-
esets and their putative association with cancer prog-
nosis. First hypothesis tests returned 66 (of the 1,082
genesets tested) as being significant for breast cancer
OS, 58 for breast cancer RFS, and 32 (of the 1,426 gene-
sets tested) for lung cancer OS with p-values p1 < 0.01.
By way of illustration, 1,082 random genesets typically
returned 61 and 55, for breast OS and RFS respectively,
as being significant at the same threshold (despite only
less than 11 being expected by chance at this p-value
threshold). When the original genesets were tested
against the second null hypothesis, only 7 and 13
genesets were significant for breast cancer OS and RFS,
respectively (p2 < 0.01). On the other hand, 18 genesets
were significant (p2 < 0.01) for lung cancer OS.
Novel significant genesets
Table 2 describes the genesets that were significant for
both hypothesis tests and remained statistically signifi-
cant after correction for multiple testing (p1 < 0.01;
FDR1 < 0.30; p2 < 0.01; FDR2 < 0.30). Additional Files 5,
6, 7, 8, and 9 provide with the identities and descrip-
tions of the genes of each significant geneset.
Revision of Chang et al. results
We then compared our methodology with that of Chang
et al., who reported a significant association (p < 0.05)
between the CSR signature and survival (Table 2) by
testing only the first null hypothesis. As might be
expected, our p-values p1 differ slightly from those
obtained by Chang et al., but in each case also appear
significant (p1 < 0.05). This confirms that the CSR signa-
ture is associated with survival time. However, these
results cannot be used to support any claim that the
biological process of the signature is also correlated with
cancer prognosis. In fact, when testing for the second
null hypothesis, two of the three estimates are not sig-
nificant. Although the response of fibroblasts to serum
appears to be highly correlated to lung cancer OS (p2 <
Table 1 Summary of results.
Survival
Estimate
Number of
genesets (p1 < 0.01)
Number of genesets
(p1 < 0.01; FDR1< 0.30)
Number of genesets
(p2 < 0.01)
Number of genesets
(p2 < 0.01;FDR2 < 0.30)
Breast OS 66 66 7 1
Breast RFS 58 58 13 0
Lung OS 32 20 18 4
For each survival estimate (i.e. breast OS, breast RFS, and lung OS), the numbers of significant genesets against the first null hypothesis (p1 < 0.01) and against
the second null hypothesis (p2 < 0.01), as well as the numbers of genesets with FDR values below the significant threshold (FDR < 0.30) for those significant
genesets are shown.
Table 2 Significant genesets and CSR comparison.
Geneset Name Survival
Estimate
Chang et al.
(p-value)
p1 FDR1 p2 FDR2
GO “fatty acid
metabolism”
Breast OS - 0.0000005 0.006 0.00014 0.30
CSR Breast OS 0.0410 0.0321000 0.280 0.14929 0.99
CSR Breast RFS 0.0130 0.0144000 0.210 0.09614 0.99
GO “receptor
mediated
endocytosis”
Lung OS - 0.0000020 0.003 0.00003 0.02
GO “brain
development”
Lung OS - 0.0000020 0.003 0.00003 0.02
GO “apical plasma
membrane”
Lung OS - 0.0001020 0.040 0.00078 0.29
KEGG “MAPK signaling
pathway”
Lung OS - 0.0001020 0.040 0.00080 0.29
CSR Lung OS 0.0014 0.0026000 0.230 0.00325 0.53
For each survival estimate, a description of the significant biologically-related genesets (p1 < 0.01; FDR1 <0 . 3 0 ;p2 < 0.01; FDR2 < 0.30) as well as a comparison of
the p-values reported by Chang et al. and our log-rank (p1) and empirical (p2) p-values for the CSR gene expression signature are shown.
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to breast cancer OS (p2 < 0.14929) and RFS (p2 <
0.09614) do not reach statistical significance, casting
s e v e r ed o u b t so nt h ea s s o c i a t i o no ft h er e s p o n s eo f
fibroblasts to serum with breast cancer OS and RFS.
This example illustrates how the non-uniform distribu-
tion of p-values1 for random genesets can lead to false
positives when using a simple statistical approach to
theme-driven survival studies.
Discussion
Unlike hypothesis-free studies in survival analysis,
theme-driven experiments aim to test whether a set of
biologically-related genes is associated with survival. In
other words, researchers seek an association between
the theme of the geneset and cancer prognosis. This
implies that such predefined genesets must be signifi-
cant predictors as determined by a survival test, which
constitutes the first null hypothesis, and also must per-
form “better” than most sets of unrelated genes, which
constitutes the second null hypothesis. If the distribu-
tion of p-values1 for random genesets is uniform, which
implies that most genes in gene expression datasets are
uninformative with respect to survival time, then the
second null hypothesis need not to be tested. However
this is rarely the case; p-values1 are usually non-uni-
formly distributed.. Therefore, any attempt to determine
significance of the theme of a geneset based on the first
hypothesis test is rendered meaningless [11]. Our results
i l l u s t r a t et h i s( F i g u r e2 ) ,a n dr a i s et h ei s s u et h a ts i m p l e
methods in theme-driven survival studies that assume
uniformity of p-values1 for random genesets may yield
false conclusions. Even when an empirical distribution is
used to calculate empirical p-values2 for the original
themes of interest, it must be noted that such p-values2
do not claim anything about the predictive power of the
themes for new sets of patients. Theoretically, this claim
has to be assessed by a prior (or posterior) independent
hypothesis test that verifies an association between a
geneset and survival time. In our study, such hypothesis
testing has been done beforehand when a p-value1 was
calculated for each geneset with a log-rank test. It is
arguable that such a simple test can have predictive
power for new patients, but it is a common procedure
in survival analysis and a thorough examination of this
topic is outside the scope of this paper.
In the analysed breast cancer dataset, many genesets
were correlated to cancer prognosis when considering p-
values1 from the first hypothesis test, both for OS and for
RFS. After testing the second null hypothesis, most of
these genesets did not reach statistical significance. This
is consistent with the skew towards low p-values1 of the
empirical distributions for random genesets (Figure 2A).
Conversely, the lung cancer dataset identified several
genesets that were significant for both the first and sec-
ond hypothesis tests. This is in turn consistent with the
lesser skew towards low p-values1 (Figure 2B).
Chang et al. have reported a correlation of their core
serum response (CSR) gene expression signature to sur-
vival time in many cancer datasets, including the same
breast and lung cancer sets used in our study. As with
other theme-driven approaches, these authors did not
consider the impact of non-uniformly distributed
p-values1 for random genesets, so they tested only the
first null hypothesis. Our findings suggest that this may
have biased their results, leading to false correlations of
the CSR signature to cancer survival. While it remains
possible that this geneset is a significant predictor of
survival in new patients for breast cancer (rejection of
the first null hypothesis), it cannot be claimed that the
biology of that geneset is relevant, given that many ran-
dom genesets achieve at least the same predictive power
(acceptance of the second null hypothesis). Our empiri-
cal approach improves upon their methodology and pro-
vides a technique to avoid this pitfall.
Although we have illustrated this issue using some com-
monly available ontologies, it is important to note that
current biological databases still offer a somewhat limited
perspective with respect to the annotation of gene func-
tion. Although biological ontologies (e.g. KEGG, Biocarta,
GO) have successfully grouped genes in terms of biological
function, such lists do not account for relationships and
dependencies among genes. Moreover, different databases
have overlapping annotations, hence analysing genesets
from various ontologies may result in redundant tests due
to duplication or multiplication of genesets. In principle
our methodology can be applied equally well to other gen-
eset collections, including proprietary sets and those avail-
able through commercial providers.
In this study we used an FDR method to control for
multiple testing, which assumes that the test statistics
are only weakly correlated [15]. This is conservative,
because it does not account for the strong dependencies
and correlations in our genesets. Filtering by use of a
non-stringent p-value (or FDR value) has been sug-
gested, since screening studies with small sample sizes
will have inherently unstable feature rankings in any sta-
tistical test; thus, reproducibility of gene expression
microarray experiments will be increased by more per-
missive thresholds [16], which is particularly important
for theme-driven cancer survival studies. Many genesets
that were significant for both hypothesis tests and also
after correction for multiple testing are biologically plau-
sible in the light of long-established biological knowl-
edge and recently published studies. Our results show a
correlation of the GO term “fatty acid metabolism” to
breast cancer overall survival. This mirrors a recent
experimental finding that reports an association between
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expression patterns of genes involved in cholesterol and
fatty acid metabolism for estrogen receptor positive
(ER+) breast tumours [17]. Our data also revealed an
association between the GO term “receptor mediated
endocytosis” and overall survival time in lung cancer.
Again, the importance of proteins involved in receptor
mediated endocytosis in lung cancer development, pro-
gression, and metastasis has been discussed in the litera-
ture [18]. Our results show additionally a relationship
between the KEGG pathway “MAPK signaling” and
overall survival in lung cancer. This is a confirmation of
the well-known oncogenic properties of the MAPK sig-
naling pathway, whose role in cancer development and
progression have been extensively addressed in the lit-
erature for lung and many other cancers [19-21]. Lastly,
our data suggests a correlation of the GO term “apical
plasma membrane” with lung cancer overall survival.
Researchers have reported that lipid trafficking to the
apical plasma membrane of pulmonary epithelial cells is
thought to be a protective stress response [22]. It can be
speculated that lung cancer cells may develop by dereg-
ulation of this mechanism.
Conclusions
Our results show that p-values1 for random genesets in
theme-driven survival studies are frequently not uni-
formly distributed. This impairs common-practice meth-
ods, and results in false positive associations between
the theme of a geneset and survival. Our proposed
empirical approach correctly avoids such pitfalls, and
the plausible biological observations obtained suggest
that a theme-driven method that correctly tests the two
inherent null hypotheses can contribute to further
understanding of the biology of cancer (and other clini-
cal survival datasets), and help bridge the gap between
gene expression predictors and biological knowledge.
Methods
Description of datasets
The study utilizes two publicly available cancer datasets.
The first is a subset of the breast cancer dataset col-
lected at The Norwegian Radium Hospital, Oslo [23].
The original dataset contained 85 tissue samples repre-
senting 84 patients, including 78 breast carcinomas, 3
fibroadenomas, and 4 normal breast tissue samples.
Given that a common interest in theme-driven experi-
ments is to distinguish subtypes of tumours, only data
from a 51-sample subset of locally advanced breast car-
cinomas were used in the current study. The gene
expression data of these 51 samples were downloaded
from the Stanford Microarray Database (SMD) [24]. The
clinical data were downloaded from the web supplement
related to this dataset.
We also obtained a lung cancer dataset collected at
the Howard Hughes Medical Institute [25]. The original
dataset consisted of 67 human lung tumours and 6 nor-
mal lung tissue samples representing 56 individuals. All
tumour samples were used in this study. The gene
expression data of the 67 samples were downloaded
from SMD. The clinical data were downloaded from the
web supplement related to this dataset.
Dataset preprocessing
T h eg e n ee x p r e s s i o nd a t af o re a c ht i s s u es a m p l eo ft h e
breast dataset were retrieved in separate Excel spread-
sheets (one spreadsheet per sample) from SMD. All
blank probes (i.e. the empty spots on the array) as well
as all customised non-mappable probes were discarded
(since genes in each geneset were represented by Entrez
Gene accession numbers, it would have been difficult to
include customised probes since no mapping tool con-
verts those to Entrez Gene accession numbers). As a
r e s u l t ,o n l yt h o s ep r o b e st h a tw e r em a p p a b l eI M A G E
clones remained in the filtered dataset. Some clones
referred to mitochondrial genes and were also dis-
carded. Only adequately measured probes were used in
this experiment, defined as a probe with fluorescent
hybridization signals at least 1.5-fold greater than the
local background signal in the reference channel. For
each adequately measured probe, the normalised log
ratio to the base 2 was extracted, whereas for inade-
quate probes a missing value (NA) was assigned. Since
the dataset was derived from four distinct batches of
cDNA microarrays, some probes only had values for a
subset of samples where such probes were unique to
the array type of those samples. In the cases where
arrays contained replicated probes (i.e. the same
IMAGE clone identifiers) a single average log ratio was
used. Only those probes for which technically adequate
measurements were obtained from at least 60% of the
samples were used [8]. To correct for any systematic
bias resulting from different amounts of cDNA in the
reference channel, the probes of the gene expression
subset were median centred (i.e. the gene-wise median
expression value of a probe was subtracted from each
log-ratio in the probe).
A similar procedure was carried out for the lung can-
cer dataset, with the only difference being the number
of microarray types from which the dataset was derived
and the number of probes in the arrays. The lung data-
set came from six different batches of cDNA microar-
rays but, as opposed to the breast dataset, all six
microarray types had approximately the same set of
probes. For this reason it was possible to use a stricter
criterion for filtering probes, with 80% of adequate mea-
surements being required for a probe to be used [8].
Both the breast and lung cancer datasets were accom-
panied by extensive clinical data. Information relevant
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its status (alive versus dead) for both datasets, with
relapse free survival (RFS) time and its status (no relapse
versus relapse) also being available for the breast cancer
dataset. The OS status of the breast dataset was simpli-
fied from four different values (0 = no evidence of dis-
ease, NED; 1 = alive with disease, AWD; 2 = dead of
disease, DOD; 3 = dead of other causes, DOC) to two
(0 = NED, AWD, DOC; 1 = DOD), since our study aim
was to focus on patient survival.
Description of genesets
Predefined sets of genes were constructed from three
distinct functional annotation groups: Biocarta pathways,
KEGG pathways, and GO terms. The genesets were
obtained from the human gene annotation file hosted at
the Cancer Genome Anatomy Project (CGAP) web site
[26]. For each functional group, all pathways or terms
were retrieved along with all genes (Entrez Gene identi-
fiers) that belonged to them. As a result, 179 genesets
from KEGG, 314 from Biocarta, and 6,032 from GO
were generated. One other set included was the original
Chang et al. gene expression signature of fibroblasts in
response to serum (CSR as defined by the authors),
which was the only geneset made up of IMAGE clone
identifiers.
Genesets that contained small (< 5) or very substantial
(> 1,000) numbers of genes were excluded, as they are
likely to be of limited biological utility. Entrez Gene
accession numbers were converted to IMAGE clone
identifiers using the web tool Clone/Gene ID Converter
[27]. A geneset was also discarded if its genes were
mapped to less than 5 or more than 2,500 probes. Addi-
tionally genesets that resulted in very uneven clusters
were discarded (see next section), as well as a small
number of genesets whose corresponding data was diffi-
cult to cluster because of excessive numbers of missing
values. Overall, 1,082 genesets were tested in the breast
cancer dataset, and 1,426 in the lung cancer set.
Patient classification and initial statistical analyses
Patient classification and statistical analyses were per-
formed with R (version 2.7) [28]. For each geneset and
each cancer dataset, the gene expression values of the
geneset probes (i.e. mapped genes) that were present in
the cancer dataset were retrieved. The samples of this
subset of gene expression data were clustered by average
linkage clustering using a correlation-based distance
matrix dxy defined by:
dxy xy  1 
where rxy is the Pearson’s correlation coefficient of x
and y. In some cases, clustering could not be performed
b e c a u s em i s s i n gv a l u e si nt h eg e n ee x p r e s s i o nd a t a
would have generated missing values in the distance
matrix. Since all pairwise distances are needed to cluster
the data, any geneset that produced a distance matrix
with missing values was discarded. After clustering,
samples were segregated into two groups based on the
first bifurcation of the hierarchical sample dendrogram,
and only cancer samples with available clinical data
were used to perform survival analysis.
Correlation of the clustered groups of patients to
survival time was assessed using a log-rank test (first
hypothesis test). Although many researchers have
chosen to use a log-rank test in their survival studies,
it has been shown that this test breaks down with
small sample sizes, such as when at least one cluster
or group of patients consists of very few samples [29].
To avoid extremely uneven clusters we discarded gen-
esets where less than 10% of the samples were in the
smaller cluster. For each survival estimate (i.e. breast
OS, breast RFS, and lung OS), a p-value p1 was
calculated.
Empirical distributions of p-values
A distribution of p-values1 for random genesets was
approximated for each type of geneset (i.e. Biocarta,
GO, and KEGG) and for each survival estimate (i.e.
breast OS, breast RFS, and lung OS) using 100,000 ran-
dom sets of unrelated genes, and their prognostic power
was assessed using the above methods (i.e. hierarchical
clustering and a log-rank test). The number of random
genesets was chosen according to a stability analysis
which showed that 100,000 permutations were enough
for the purposes of our study (Additional Files 10, 11,
12). The permutation results were used to generate
“Biocarta-like”, “GO-like”,a n d“KEGG-like” empirical
distributions of p-values1 for both breast and lung can-
cer datasets. A distinction was made for the three dif-
ferent types of genesets because the “universe” of genes
(i.e. the genes that have an annotation) is not the same.
For example, the universe of GO genes contains
approximately 14,000 genes, whereas the universe of
Biocarta genes only has around 3,000 genes. Selecting
genes from a wider, or more restricted, universe than
the real one may result in biased estimates [30]. Addi-
tionally, since an association is present between geneset
size and significance (Figure 1, Additional Files 1, 2),
the sizes of the randomly generated genesets were
matched to those of the original genesets so as to
include the same proportion of geneset sizes in each
distribution.
Association between the theme of a geneset and survi-
val time was assessed with an empirical test based on
the previously modelled distributions (second hypothesis
test). An empirical p-value p2 was calculated for each
survival estimate for the original 1,082 and 1,426
Czwan et al. BMC Bioinformatics 2010, 11:19
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Page 8 of 11genesets analysed in breast and lung cancer, respectively,
which was defined by:
p
pp
p
2
111
1



where pp 11
 is the number of random genesets from
the appropriate empirical distribution which yielded p-
values less than or equal to the p-value p1 obtained from
the log-rank test for the geneset of interest at the first
hypothesis test, and p1
 is the total number of random
genesets. To control for the multiple testing of genesets
in each hypothesis test we used a false discovery rate
(FDR) method, defined as the proportion of expected
false positive findings over the total number of alternative
hypotheses accepted at the specified significance level
[31]. FDR1 and FDR2 values were calculated for p-values
of the first and second hypothesis tests, respectively.
In order to compare our CSR signature results to those
of Chang et al., three CSR-like empirical distributions of
p-values1 for random genesets (breast cancer OS, breast
cancer RFS, and lung cancer OS), were constructed from
100,000 random sets of unrelated genes. For each distribu-
tion, the randomly generated genesets were chosen to
match the size of the CSR signature. Furthermore, the uni-
verse of genes was designed so as to only include genes
that could have been selected in the original experiment,
based on the procedures described by Chang et al.
Additional file 1: Association between geneset size and significance
for breast cancer RFS. For each type of geneset (i.e. Biocarta, GO, and
KEGG), sets of random genes of sizes 20, 75, 150, 300, and 500 (the latter
omitted for Biocarta because the pool of genes was too small) consisting
of 10,000 genesets for each size were generated. For each geneset,
hierarchical clustering was performed to segregate samples into two
groups, a subsequent log-rank test was performed to assess a difference
in prognosis between both groups, and the p-value1 was recorded. The
negative base 10 logarithms of the p-values1 are plotted against geneset
size. Biocarta-like genesets appear to be more significant around length
= 150 (A); GO-like genesets do not show a clear correlation of
significance to geneset size (B); KEGG-like genesets seem to be more
significant as size becomes smaller (C).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S1.PDF]
Additional file 2: Association between geneset size and significance
for lung cancer OS. For each type of geneset (i.e. Biocarta, GO, and
KEGG), sets of random genes of sizes 20, 75, 150, 300, and 500 (the latter
omitted for Biocarta because the pool of genes was too small) consisting
of 10,000 genesets for each size were generated. For each geneset,
hierarchical clustering was performed to segregate samples into two
groups, a subsequent log-rank test was performed to assess a difference
in prognosis between both groups, and the p-value1 was recorded. The
negative base 10 logarithms of the p-values1 are plotted against geneset
size. Biocarta-like genesets seem to be more significant as size becomes
smaller (A); GO-like genesets seem to be more significant as size
becomes smaller (B); KEGG-like genesets seem to be more significant as
size becomes smaller (C).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S2.PDF]
Additional file 3: Empirical p-value1distributions of random
genesets for breast cancer RFS. Relative frequency density distributions
are shown for breast cancer RFS (A). The relative frequency density
estimate with a bandwidth equal to 0.01 is plotted for each empirical
distribution (i.e. Biocarta-like, GO-like, KEGG-like, and CSR-like). A uniformly
distributed empirical distribution would result in p-values1 at the same
frequency across the entire range 0 < p < 1, (dashed line in (A)). An
ordered plot of empirical p-value1 distributions versus the uniform
distribution is shown for breast cancer RFS (B). The permuted p-values1
used to model each distribution (i.e. Biocarta-like, GO-like, KEGG-like, and
CSR-like) are plotted against random p-values from a uniform
distribution. An x = y line would be expected if the empirical
distributions were uniformly distributed.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S3.TIFF]
Additional file 4: Empirical p-value density distributions of random
genesets for breast cancer OS and lung cancer OS (negative
logarithmic scale). Relative frequency density distributions are shown
for breast cancer OS (A) and for lung OS (B). For each survival estimate
(i.e. breast cancer OS, and lung cancer OS), the relative frequency density
estimate with a bandwidth equal to 0.01 is plotted for each empirical
distribution (i.e. Biocarta-like, GO-like, KEGG-like, and CSR-like) on a
negative logarithmic to the base 10 scale. A uniformly distributed
empirical distribution would result in p-values1 at the same frequency
across the entire range -log(0) > -log(p) > -log(1) (dashed line in (A) and
(B)).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S4.PDF]
Additional file 5: Genes in GO geneset ‘fatty acid metabolism’. A tab
separated text file that shows the identities and descriptions of the
genes of the GO geneset ‘fatty acid metabolism’ present in the breast
cancer microarray dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S5.TXT]
Additional file 6: Genes in GO geneset ‘receptor mediated
endocytosis’. A tab separated text file that shows the identities and
descriptions of the genes of the GO geneset ‘receptor mediated
endocytosis’ present in the lung cancer microarray dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S6.TXT]
Additional file 7: Genes in GO geneset ‘brain development’. A tab
separated text file that shows the identities and descriptions of the
genes of the GO geneset ‘brain development’ present in the lung cancer
microarray dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S7.TXT]
Additional file 8: Genes in GO geneset ‘apical plasma membrane’.A
tab separated text file that shows the identities and descriptions of the
genes of the GO geneset ‘apical plasma membrane’ present in the lung
cancer microarray dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S8.TXT]
Additional file 9: Genes in KEGG geneset ‘MAPK signaling’. A tab
separated text file that shows the identities and descriptions of the
genes of the KEGG geneset ‘MAPK signaling’ present in the lung cancer
microarray dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S9.TXT]
Additional file 10: Stability analysis to assess the overall number of
permutations using the GO genesets for breast cancer OS. For each
original GO geneset, an empirical p-value2 was calculated from different
distributions based on different numbers of random genesets. The
negative logarithms of the p-values2 to the base 10 from 100 k (i.e.
Czwan et al. BMC Bioinformatics 2010, 11:19
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Page 9 of 11100,000) permutations are plotted against the negative logarithms of
p-values2 to the base 10 from different permutations (A, B, C, D, and E). If
the empirical p-values2 from all distributions were equal, an x = y line
would be observed. As the number of random genesets used to model
the distributions increase from 1 k to 50 k, the empirical p-values2
resemble those of the 100 k permutations (A, B, C, and D). Increasing the
number of permutations from 100 k to 200 k does not considerably
change the significance of the GO genesets (E). The empirical p-values2
obtained for the GO genesets from all the permutations show that
empirical p-values2 from 200 k, 100 k, and 50 k distributions are all very
consistent (F).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S10.PDF]
Additional file 11: Stability analysis to assess the overall number of
permutations using the GO genesets for breast cancer RFS. For each
original GO geneset, an empirical p-value2 was calculated from different
distributions based on different numbers of random genesets. The
negative logarithms of the p-values2 to the base 10 from 100 k (i.e.
100,000) permutations are plotted against the negative logarithms of
p-values2 to the base 10 from different permutations (A, B, C, D, and E). If
the empirical p-values2 from all distributions were equal, an x = y line
would be observed. As the number of random genesets used to model
the distributions increase from 1 k to 50 k, the empirical p-values2
resemble those of the 100 k permutations (A, B, C, and D). Increasing the
number of permutations from 100 k to 200 k does not considerably
change the significance of the GO genesets (E). The empirical p-values2
obtained for the GO genesets from all the permutations show that
empirical p-values2 from 200 k, 100 k, and 50 k distributions are all very
consistent (F).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S11.PDF]
Additional file 12: Stability analysis to assess the overall number of
permutations using the GO genesets for lung cancer OS. For each
original GO geneset, an empirical p-value2 was calculated from different
distributions based on different numbers of random genesets. The
negative logarithms of the p-values2 to the base 10 from 100 k (i.e.
100,000) permutations are plotted against the negative logarithms of
p-values2 to the base 10 from different permutations (A, B, C, D, and E). If
the empirical p-values2 from all distributions were equal, an x = y line
would be observed. As the number of random genesets used to model
the distributions increase from 1 k to 50 k, the empirical p-values2
resemble those of the 100 k permutations (A, B, C, and D). Increasing the
number of permutations from 100 k to 200 k does not considerably
change the significance of the GO genesets (E). The empirical p-values
2obtained for the GO genesets from all the permutations show that
empirical p-values2 from 200 k, 100 k, and 50 k distributions are all very
consistent (F).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
19-S12.PDF]
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